{"id":3287,"date":"2020-06-18T12:23:11","date_gmt":"2020-06-18T11:23:11","guid":{"rendered":"https:\/\/ibb.uab.cat\/?p=3287"},"modified":"2020-06-18T12:24:16","modified_gmt":"2020-06-18T11:24:16","slug":"development-of-new-nanotechnological-based-enzyme-replacement-therapy-for-parkinsons-disease-nano-ert","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2020\/06\/18\/development-of-new-nanotechnological-based-enzyme-replacement-therapy-for-parkinsons-disease-nano-ert\/","title":{"rendered":"Development of new nanotechnological based Enzyme Replacement Therapy for Parkinson\u2019s disease (NANO-ERT)"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong><em>The BBVA foundation granted the NANO-ERT project in the 2019 call (Ayudas a Equipos de Investigaci\u00f3n Cient\u00edfica en Biomedicina) to a consortium participated by Vall d&#8217;Hebron Research Institute (VHIR), Universitat Aut\u00f3noma de Barcelona (IBB-UAB) and ICN2.<\/em><\/strong><strong><em>\u00a0<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">The project \u2018Development of new nanotechnological based Enzyme Replacement Therapy for Parkinson\u2019s disease: restoration of lysosomal glucocerebrosidase activity through enzyme-polymer nanoconjugation of GBA (NANO-ERT)\u2019 will be funded with \u20ac 124,872. The BBVA Foundation\u2019s has selected 5 projects out of the 134 presented in the Biomedicine area.<\/p>\n<p style=\"text-align: justify;\">The NANO-ERT project was focused on the development of smart nanoformulations to achieve a new therapy against Parkinson&#8217;s based on Enzimatic Replacement Therapy (ERT). The project, coordinated by the group Neurodegenerative Diseases (Vall d`Hebron-Institut de Recerca, VHIR) and led by <strong>Dr. Marta Mart\u00ednez Vicente<\/strong>, has been stablished in collaboration with the Nanostructured Functional Materials group (NANOSFUN, ICN2) led by <strong>Dr. Daniel Ruiz-Molina<\/strong> and the group Protein Engineering and Proteomics led by <strong>Dr. Julia Lorenzo<\/strong> (Institut de Biotecnologia i Bioqu\u00edmica, IBB-UAB).<\/p>\n<p style=\"text-align: justify;\"><img loading=\"lazy\" class=\"wp-image-3288 aligncenter\" src=\"https:\/\/ibb.uab.cat\/wp-content\/uploads\/noticia-julia-lorenzo.jpg\" alt=\"\" width=\"852\" height=\"482\" srcset=\"https:\/\/ibb.uab.cat\/wp-content\/uploads\/noticia-julia-lorenzo.jpg 451w, https:\/\/ibb.uab.cat\/wp-content\/uploads\/noticia-julia-lorenzo-300x170.jpg 300w\" sizes=\"(max-width: 852px) 100vw, 852px\" \/><\/p>\n<p style=\"text-align: justify;\">The NANO-ERT project proposes the design and development of a new enzyme replacement therapy based on the administration of recombinant GBA protein, since it is known that the presence of mutations in the lysosomal enzyme GBA is the main genetic risk for developing Parkinson\u2019s disease. The objective is to use nanotechnological approximations to improve ERT applications. The aim is to increase the metabolic stability of GBA and improve its ability to cross the blood-brain barrier and reach the brain. The technology will be validated in animal models and will serve as proof of concept in the development of protein transport systems in the central nervous system in the context of neurodegenerative diseases.<\/p>\n<p style=\"text-align: justify;\">\u00a0<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.fbbva.es\/noticias\/concedidas-5-ayudas-a-equipos-de-investigacion-cientifica-en-biomedicina\/\">https:\/\/www.fbbva.es\/noticias\/concedidas-5-ayudas-a-equipos-de-investigacion-cientifica-en-biomedicina\/<\/a><\/p>\n<p style=\"text-align: justify;\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The BBVA foundation granted the NANO-ERT project in the 2019 call (Ayudas a Equipos de Investigaci\u00f3n Cient\u00edfica en Biomedicina) to a consortium participated by Vall d&#8217;Hebron Research Institute (VHIR), Universitat Aut\u00f3noma de Barcelona (IBB-UAB) and ICN2.\u00a0 The project \u2018Development of new nanotechnological based Enzyme Replacement Therapy for Parkinson\u2019s disease: restoration of lysosomal glucocerebrosidase activity through [&hellip;]<\/p>\n","protected":false},"author":65,"featured_media":3288,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3287"}],"collection":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/comments?post=3287"}],"version-history":[{"count":2,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3287\/revisions"}],"predecessor-version":[{"id":3290,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3287\/revisions\/3290"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media\/3288"}],"wp:attachment":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media?parent=3287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/categories?post=3287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/tags?post=3287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}